Showing 1 – 20 of 20
Relevance | Newest | Oldest |
  • JAMA September 8, 2015

    Figure: Advanced Multimodal Imaging in a Case of a 56-Year-Old Left-Handed Woman With Medically Refractory Epilepsy

    A, Magnetoencephalography identified a few possible abnormal discharges in the left temporal lobe, shown here as fused images with high-resolution T1-weighted anatomical magnetic resonance (MR) images. B, Metabolic imaging with simultaneous 18F-fluorodeoxyglucose–positron emission tomography/magnetic resonance imaging (18FDG PET/MRI) demonstrated hypometabolism in the left posterior medial temporal lobe. Arrowheads indicate decreased glucose uptake in the left posterior medial temporal lobe. C, Gradient echo MR image obtained at 7 T demonstrated extensive blood products abutting the left hippocampal tail along with a possible large draining vein. D, MR angiography performed at 7 T showed no abnormal vasculature in the left mesial temporal lobe. E, Task-based fMRI for presurgical planning showed right hemisphere activation corresponding to language eloquent cortex. F, Functional connectivity analysis with resting-state fMRI showed decreased connectivity throughout the default mode network in the left cerebral hemisphere. Surgical resection of the lesion in the left mesial temporal lobe demonstrated a thrombosed arteriovenous malformation.
  • Outcome After Conservative Management or Intervention for Unruptured Brain Arteriovenous Malformations

    Abstract Full Text
    free access
    JAMA. 2014; 311(16):1661-1669. doi: 10.1001/jama.2014.3200

    Al-Shahi Salman and coauthors conducted a population-based cohort study of 204 Scottish residents aged 16 years or older to compare the long-term outcomes of conservative management vs interventional treatment for unruptured brain arteriovenous malformations.

  • Treatment of Brain Arteriovenous Malformations: A Systematic Review and Meta-analysis

    Abstract Full Text
    free access is expired quiz
    JAMA. 2011; 306(18):2011-2019. doi: 10.1001/jama.2011.1632
  • CONGENITAL VASCULAR ANOMALIES

    Abstract Full Text
    JAMA. 1951; 145(12):869-875. doi: 10.1001/jama.1951.02920300009002
  • Bevacizumab in Patients With Hereditary Hemorrhagic Telangiectasia and Severe Hepatic Vascular Malformations and High Cardiac Output

    Abstract Full Text
    free access
    JAMA. 2012; 307(9):948-955. doi: 10.1001/jama.2012.250
  • The Blalock-Taussig-Thomas Collaboration

    Abstract Full Text
    JAMA. 2008; 300(3):328-330. doi: 10.1001/jama.300.3.328
  • Manifestations of Chronic Disease During Pregnancy

    Abstract Full Text
    free access is expired quiz
    JAMA. 2005; 294(21):2751-2757. doi: 10.1001/jama.294.21.2751
  • Progress in Neurological Surgery

    Abstract Full Text
    JAMA. 1971; 218(4):599-600. doi: 10.1001/jama.1971.03190170077039
  • Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2016; 316(9):943-951. doi: 10.1001/jama.2016.11724

    This randomized clinical trial assesses whether topical therapy with either bevacizumab, estriol, or tranexamic acid that have differing mechanisms of action is effective in reducing hereditary hemorrhagic telangiectasia–related epistaxis in 121 adult patients treated at 6 US centers of excellence.

  • Effect of Bevacizumab Nasal Spray on Epistaxis Duration in Hereditary Hemorrhagic Telangectasia: A Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2016; 316(9):934-942. doi: 10.1001/jama.2016.11387

    This randomized trial investigates the efficacy of 3 different doses of bevacizumab nasal spray for reducing epistaxis duration in patients with hereditary hemorrhagic telangiectasia (HHT).

  • Afecciones vasculares quirurgicas del encefalo

    Abstract Full Text
    JAMA. 1948; 137(4):419-419. doi: 10.1001/jama.1948.02890380089031
  • Postoperative Complications of Intracranial Neurological Surgery

    Abstract Full Text
    JAMA. 1983; 249(22):3100-3100. doi: 10.1001/jama.1983.03330460072044
  • JAMA April 23, 2014

    Figure 3: Progression to the Secondary Outcome During 12 Years of Prospective Follow-up

    The secondary outcome was first occurrence after inception of a nonfatal intracranial hemorrhage, cerebral infarction, or persistent/progressive nonhemorrhagic focal neurological deficit or death due to a brain arteriovenous malformation or intervention complication. Error bars indicate 95% CIs of the cumulative proportions at 4 and 12 years after inception.
  • JAMA April 23, 2014

    Figure 1: Participant Flow

    bAVM indicates brain arteriovenous malformationaTen secondary outcomes were due to bAVM and 28 were due to intervention complications.bFive patients experiencing bAVM hemorrhage during conservative management subsequently had intervention but remained in the conservative management group for analysis of the primary outcome.cAll 14 secondary outcomes were due to bAVM.
  • Red Papules on the Tongue of a Patient With Hemiparesis

    Abstract Full Text
    JAMA. 2014; 312(7):741-742. doi: 10.1001/jama.2014.1658
  • Structural Heart Disease Interventions

    Abstract Full Text
    JAMA. 2012; 308(17):1812-1813. doi: 10.1001/jama.308.17.1812
  • Acute-Onset Floaters and Flashes: Is This Patient at Risk for Retinal Detachment?

    Abstract Full Text
    is expired quiz has multimedia
    JAMA. 2009; 302(20):2243-2249. doi: 10.1001/jama.2009.1714
  • Neurology

    Abstract Full Text
    JAMA. 2006; 296(19):2379-2384. doi: 10.1001/jama.296.19.2382
  • Does This Patient Have Clubbing?

    Abstract Full Text
    JAMA. 2001; 286(3):341-347. doi: 10.1001/jama.286.3.341
  • Pregnancy-Related Death Associated With Heparin and Aspirin Treatment for Infertility, 1996

    Abstract Full Text
    free access
    JAMA. 1998; 279(23):1860-1861. doi: 10.1001/jama.279.23.1860-JWR0617-4-1